Course of thrombin activation markers in patients implanted with Palmaz—Scnatz stents: first experiences with a post-interventional anticoagulation regimen

Haushofer, Alexander; Halbmayer, Walter Michael; Dittel, M; Prachar, H; Mlczoch, J; Fischer, Michael

doi:10.1097/00001721-199410000-00004

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brack et al 25 found that AT III levels are not a good pre dictor of restenosis after percutaneous transluminal coronary angioplasty (PTCA). Haushofer et al 26 found that preoperative TAT complexes do not predict which patients will undergo thrombotic stent failure. Yet Gulba and associates 27 demonstrated that restenosis may occur in a single vessel angioplasty if TAT complex levels are greater than 6 μg/L.…”

Section: Review Of the Literaturementioning

confidence: 99%

Is Low AT III a Significant Risk Factor for Coronary Artery Disease? Anecdotal Observations

Dickerson¹

1997

Semin Thromb Hemost

View full text Add to dashboard Cite

I report on my 6-year experience identifying the correlation of low antithrombin III (AT III) levels with coronary artery disease in a rural Missouri family practice setting. I measured plasma AT III levels in 78 patients who were at risk for coronary artery disease. I also tracked lipid profiles, HBA1C, blood pressure, body mass index, hostility, and nicotine use. I measured AT III levels using Baxter Diagnostic AG Dade antithrombin III chromogenic coagulation assays of antithrombin III (normal range, 88% to 126%) at the Boone County Hospital Laboratory, Columbia, Missouri. I analyzed the patient records and looked for the worst recording of each of the above risk factors, selecting the highest blood pressure, total cholesterol, LDL cholesterol, triglycerides, HBA1C, weight, and age. I selected the lowest AT III level, which often occurred when the patient was stressed. When the worst risk factors were picked over a long period of time, low AT III correlated with an arbitrary coronary artery disease scale 24% of the time. This negative correlation (r = -.49) was higher than any other risk factor in these selected patients.

show abstract

Section: Review Of the Literaturementioning

confidence: 99%

Is Low AT III a Significant Risk Factor for Coronary Artery Disease? Anecdotal Observations

Dickerson¹

1997

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…In patients after coronary stenting a highly significant correlation between the anticoagulant response represented by the activated partial thromboplastin time (APTT) with the heparin level, body weight, height, and body surface area could be demonstrated (3,4). For clinical efficacy of heparin therapy it is necessary to maintain an anticoagulant effect above a minimum level (5).…”

Section: Monitoring Of High-dose Intravenous Heparinmentioning

confidence: 99%

State-of-the-Art Review : Monitoring of High-Dose Intravenous Heparin Therapy—A Contribution to the Safety of Heparin Monitoring

Haushofer¹,

Halbmayer²,

Radek³

et al. 1996

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Whenever unfractionated heparin (UFH) is administered i.v. in therapeutic doses, therapeutic drug monitoring of the anticoagulant response should be mandatory and the dose should be adjusted accordingly. UFH therapy is usually monitored by the activated partial thromboplastin time (APTT). A 1.5-to 2.5-fold prolongation of APTT has become generally accepted as an indicator of effective i.v. anticoagulation, but it has become common to recommend this ratio without testing the APTT reagents used for their heparin sensitivity and for their actual therapeutic APTT ratio (actual APTT: normal control APTT). Internal heparin sensitivity testing of APTT reagents is managed using heparin sensitivity curves obtained from heparin-spiked normal plasma pool.The most common APTT reagents in Austria and a newly developed double activated APTT reagent were tested for their heparin sensitivity and therapeutic ratios on different automated analyzers, depending on their optical and chemical conditions. Also, newly developed, commercially prepared heparin standards (0.19, 0.52, 0.86 IU heparin/ml plasma) were tested. APTT reagents differ in their heparin sensitivity and therapeutic ratio; variations in heparin sensitivity are also seen between different analyzers. Therefore, therapeutic ratio should regularly be checked and the literature should always state which APTT reagent was used on which instrument.

show abstract

Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stenting

Neumann

Gawaz

Ott

et al. 1996

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

Course of thrombin activation markers in patients implanted with Palmaz—Scnatz stents: first experiences with a post-interventional anticoagulation regimen

Cited by 5 publications

References 0 publications

Is Low AT III a Significant Risk Factor for Coronary Artery Disease? Anecdotal Observations

Is Low AT III a Significant Risk Factor for Coronary Artery Disease? Anecdotal Observations

State-of-the-Art Review : Monitoring of High-Dose Intravenous Heparin Therapy—A Contribution to the Safety of Heparin Monitoring

Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stenting

Contact Info

Product

Resources

About